Based on the presented observations, we have synthesized the covalently linked melanoma antigen, gp100, with cationic liposomes, as a cancer vaccine co-administered with CpG-ODN for in vivo delivery to DCs to improve the immunotherapeutic effect of anti PD-1 therapy. This evidence concerns the gene PMEL and melanoma.